Greater Freiburg Area
Experienced executive and healthcare analyst with proven record in business development and international marketing. 33 years of experience in pharmacology and molecular oncology. Professional strongpoints: drug discovery and development, strategic development, precision medicine, preclinical cancer models, oncology, immuno-oncology, biomarker science, business development, R&D collaboration, co-promotion and co-marketing alliances. Joined Oncotest (a Charles River Company now) in 2002 after working in Boehringer Ingelheim's oncology program for eight years. Responsible for partnering and business development activity, strategy review cycle, portfolio management and oversight of all project initiatives, including line of responsibility for the team of project managers and experts at Oncotest.
33 years of experience in pharmacology and molecular oncology. Drug discovery and development. Strategic development Precision medicine. Preclinical cancer models. Oncology. Immuno-oncology. Biomarker science. Business development. R&D collaboration, co-promotion and co-marketing alliances. Management of complex project portfolios consisting of multiple concurrent initiatives designed to achieve specific milestones within budgetary requirements. Optimization of organizational structure to improve efficiency, streamline processes, and reduce overhead costs. Evaluation of emerging industry trends to inform business strategy adjustments proactively. Negotiation of favorable contracts with suppliers to reduce procurement costs without compromising quality or service levels. Delivering compelling presentations at industry conferences that showcased thought leadership while promoting brand awareness among potential clients and partners.
Established strategic goals for broad-scale research through acquisition of appropriate funding and program support. Conducted risk assessments for research where applicable. Edited, reviewed and supported grant applications to provide comprehensive funding for research objectives. Analyzed findings and reports from researchers in program and interpreted for supervisory staff. Managed budgets for multiple projects, ensuring cost-effective utilization of resources without compromising quality or scope. Balanced multiple priorities while adhering to strict deadlines for deliverables with minimal supervision. Spearheaded initiatives to improve internal communication within the department, resulting in enhanced collaboration among team members. Reviewed staff performance on a regular basis, providing constructive feedback and coaching to ensure continuous improvement in skills and productivity levels. Created compelling reports summarizing key findings from various studies that informed decision-making processes at executive levels. Presented research findings at national conferences, raising awareness of innovative discoveries and promoting collaboration within the industry. Established collaborative partnerships with external organizations to bolster research capabilities and drive innovation.
In 2002 I joined Oncotest as a Director of Drug Discovery. In this capacity I have an overall responsibility for the design and management of the contract research projects, including initial scooping, execution and reporting. It is company policy that a director will take primary responsibility for client liaison for each project, consultation, study design and project management. My background means that I appreciate the constraints that exist within big organizations. My policy is to work closely with clients to understand their business and the relevant issues and my strength lies in my ability to use my contacts in science communication, science policy and research worlds to effectively put together teams and manage projects from start to finish.
Laboratory head and project coordinator in drug discovery and drug development at the Oncology Department of Boehringer Ingelheim. Coordinated predevelopment, leading a team consisting of chemists, screeners, pharmacokineticists, animal pharmacologists and toxicologists during the phases of assay development, high throughput screening, lead ID and lead optimization. From 1999, worked in the then newly formed Department of Exploratory Research responsible for assay development for histone deacetylases, lead ID, coordination of target ID at the Oncology department of Boehringer Ingelheim. While at Boehringer Ingelheim, I attended numerous special professional courses of training in management and leadership.